Canaccord raised the firm’s price target on Zimmer Biomet to $150 from $130 and keeps a Hold rating on the shares. The analyst said they put up a solid Q1 in spite of continued macro headwinds, materially outperforming given lighter comps, strong new product uptake, and better-than- expected procedural recovery.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target raised to $160 from $144 at Raymond James
- Zimmer Biomet price target raised to $172 from $145 at Baird
- Zimmer Biomet price target raised to $160 from $145 at JMP Securities
- Zimmer Biomet price target raised to $152 from $136 at Bernstein
- Zimmer Biomet management to meet with Oppenheimer
